CVS Health Raises 2026 Guidance After Strong Q1 Results
CVS Health raised its full-year 2026 adjusted earnings guidance after reporting strong Q1 results, with revenue of $91.2 billion. The company cited improved performance at Aetna and continued execution at Caremark.
Key Numbers
CVS Health (NYSE:CVS) reported strong first-quarter results for 2026, prompting management to raise its full-year adjusted earnings outlook. Q1 revenue reached $91.2 billion, driven by improved performance at Aetna and continued execution at Caremark. The stock rose 2.3% in after-hours trading.
Key Financial Results
| Metric | Q1 2026 | YoY Change |
|---|---|---|
| Revenue | $91.2B | +8.5% |
| Adjusted Net Income | $3.2B | +12% |
| Adjusted EPS | $2.45 | +$0.30 |
Highlights from the Call
- Aetna Improvement: Medical loss ratio (MLR) improved to 84.5% from 86.2% a year ago, reflecting better cost management.
- Caremark Strength: Pharmacy benefit management revenue grew 9% due to new contracts.
- Pharmacy Resilience: Retail operations maintained stable margins despite pricing pressure.
Forward Guidance
CVS raised its full-year 2026 adjusted EPS guidance to $9.50-$9.80, up from the prior range of $9.35-$9.65. The increase reflects confidence in sustained operational improvement.
Stock Impact
The stock rose 2.3% after the announcement, indicating positive investor reception. However, shares remain down about 5% year-to-date.
What This Means for Investors
The results suggest that CVS's strategy to improve insurance margins and expand pharmacy services is gaining traction. The guidance raise bolsters confidence in the company's ability to meet its targets, but investors should watch for competition in the health insurance sector.
Frequently Asked Questions
Found this useful? Share it